Sat, Jan 31, 2015, 6:58 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • carylindsay@sbcglobal.net carylindsay Nov 22, 2004 10:06 AM Flag

    Riding Wrong Horse in this RACE!!!

    On November 10th, Alnylam (ALNY)issued a PR claiming to be the first company to demonstrate in vivo that RNA Interference was a potential new treatment method to lower the expression of a clinically relevant target.

    I find this interesting since it appears that Sirna Therapeutics (RNAI) has published several articles and even presented data at numerous medical forums prior to this November event for (ALNY). Also it appears that with (ALNY) using an enormous dosing of 50 mg/kg as compared to (RNAI's) miniscule 3 to 5 mg/kg, (RNAI) obtained more positive data than (ALNY). (RNAI) got a 95% reduction in expression of green fluorescent protein in the liver for up to 22 days from a single dosing in a transgenic mouse expressing green fluorsescent protein, compared to only 68% reduction achieved by (ALNY) using three doses that were 10 times higher.

    Appears we might have a patent fight on our hands, that is if this new approach has merit and is worth the litigation expense. Barron's has a very positive article today about (ALNY), but they never mention (RNAI). IMO it seems that (RNAI) is the one to follow.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't know where to start:

      "enormous dosing of 50 mg/kg as compared to (RNAI's) miniscule 3 to 5 mg/kg"

      This is a minor difference in PK/PD terms

      "got a 95% reduction in expression of green fluorescent protein in the liver for up to 22 days from a single dosing in a transgenic mouse expressing green fluorsescent protein"

      Err- would you rather knock down ApoB, a naturally occuring disease related gene, or GFP, a jelly-fish gene genetically introduced into the mouse? ALNY went after a ApoB and showed a 'clinically relevant' decrease in serum.

      "RNA Interference was a potential new treatment method to lower the expression of a clinically relevant target"

      Since when is a jelly-fish protein a clinically relevant target?

    • Although alnylam touts a clinically relevant route of admin, 50 mg/kg is not a clinically relevant dose.

      RNAI is a promising technology, but I do not see how alny can make these claims in the face of other scientific and competitive evidence.

    • WATCH OUT CLICALTRIALS SOON DEAR

 
ALNY
93.83+0.400(+0.43%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.